A Phase Ib, open lable trial of orally administered DUR-928 for the treatment of non-alcoholic steatohepatitis (NASH) patients
Latest Information Update: 18 Aug 2021
At a glance
- Drugs Larsucosterol (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions; Biomarker; Pharmacokinetics; Proof of concept
- Sponsors DURECT Corporation
Most Recent Events
- 26 Jun 2021 Results for further analysis of efficacy signals from this trial, presented at The International Liver Congress 2021
- 23 Jun 2021 According to a DURECT Corporation media release, data from this study presented at the 2021 International Liver Conference (EASL).
- 23 Jun 2021 Results published in the DURECT Corporation media release